Takeda Lung Cancer Drug Motesanib Flunks Late Stage Trial

Takeda Announces Phase 3 MONET-A Study Evaluating Motesanib in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint CAMBRIDGE, MA, USA and OSAKA, Japan I February 17, 2015 I Takeda Pharmaceutical Company Limited today announced the primary endpoint of progression-free survival was not met in the Phase 3 MONET-A study of patients with stage IV non-squamous non-small cell lung cancer who were randomized to treatment with investigational motesanib in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin. As a result, Takeda has elected to terminate the MONET-A trial, and will report on the full trial results once available.

http://ift.tt/1Fn7lQn